PRODUCTION OF 43SC RADIONUCLIDE AND ITS USE IN POSITRON EMISSION TOMOGRAPHY

• US 20190307909A1
• Filed: 05/21/2019
• Published: 10/10/2019
• Est. Priority Date: 05/13/2014
• Status: Active Application

• Current Assignee: Paul Scherrer-Institut (Schweizerische Eidgenossenschaft)
• Original Assignee: Paul Scherrer-Institut (Schweizerische Eidgenossenschaft)
• Inventors: TUERLER, ANDREAS, VAN DER MEULEN, NICHOLAS, BUNKA, MARUTA
• Application Number:
  US16/417,956
• Publication Number:
  US 20190307909A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 51/088 conjugates with carriers being peptides, polyamino acids or proteins antibodies A61K51/10
• CPC Class Codes: C07F 5/00 Compounds containing elements of Groups 3 or 13 of the Periodic Table
• CPC Class Codes: G21G 1/001 Recovery of specific isotopes from irradiated targets
• CPC Class Codes: G21G 1/10 by bombardment with electrically charged particles irradiation devices G21K5/00
• CPC Class Codes: G21G 2001/0094 Other isotopes not provided for in the groups listed above

Abstract

The radionuclide 43Sc is produced at commercially significant yields and at specific activities and radionuclidic purities which are suitable for use in radiodiagnostic agents including imaging agents. In a method, a solid target having an isotopically enriched target layer prepared on an inert substrate is positioned in a specially configured target holder and irradiated with a charged-particle beam of protons or deuterons. The beam is generated using an accelerator such as a biomedical cyclotron at energies ranging from 3 to about 22. MeV. The method includes the use of three different nuclear reactions: a) irradiation of enriched 43Ca targets with protons to generate the radionuclide 43Scin the nuclear reaction 43Ca (p,n)43Sc, b) irradiation of enriched 42Ca targets with deuterons to generate the radionuclide 43Sc in the nuclear reaction 42Ca(d,n)43Sc, and c) irradiation of enriched 46Ti targets with protons to generate the radionuclide 43Sc in the nuclear reaction 46Ti (p,a) 43Sc.

Claims

1. A radiopharmaceutical to be applied in positron emission tomography, comprising:

a radiometal-based radiopharmaceutical agent containing a bifunctional chelator namely a DOTA ligand (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) conjugated to a targeting vector and 43Sc being bound to a chelating agent.

2. The radiopharmaceutical according to claim 1, wherein said targeting vector is selected from the group consisting of an antibody, a peptide, nanoparticles, a vitamin and their derivates.

3. A radiopharmaceutical, comprising:

a dose for one positron emission tomography having 43Sc to a radio content of 100 to 500 MBq.

4. The radiopharmaceutical according to claim 3, wherein said radio content is about 200 MBq.